The FDA has approved the SAPIEN 3 platform, a TAVR therapy, for patients with severe aortic stenosis without symptoms.

In patients greater than age 65, more than 90% of aortic stenosis involves trileaflet valves which have developed heavy calcification. [5] In these instances the calcium deposits are thought to ...

MONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe ...

From genetic risks to inflammation markers, uncover the latest insights in cardiovascular prevention that every primary care ...

In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved the use of the SAPIEN 3 transcatheter aortic valve ... aortic stenosis patients could lead to changes in clinical ...

The aortic valve opens to let blood flow to the rest of your ... We’re carrying out research with BHF funding to look at how changes in the heart caused by aortic stenosis affects outcomes after TAVI.

Introduction: Aortic stenosis (AS) is a valvular heart disease that obstructs normal blood flow from the left ventricle to the aorta due to pathological changes in the valve, leading to impaired ...

19 Moreover, diastolic apical untwisting is prolonged in comparison with normal subjects and a significant relationship between delayed LV untwisting and increased LV filling pressures was found in ...

By using a stethoscope, healthcare providers can listen for heart valve ... Aortic stenosis Cardiac amyloidosis Fabry disease Another possible cause is known as "athlete's heart." Just as exercise ...